In this Q&A, Andrea Valente, CEO of uMotif, discusses what it takes to build genuine trust between patients and sites, why making technology easier to use isn't the same as making patient-site ...
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site ...
In part three of her DPHARM interview, Andrea Valente, CEO of uMotif, explains why truly understanding the patient journey ...
In part two of her DPHARM interview, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't ...
In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Cecilia Xi, PhD, VP of clinical and scientific affairs at Vivalink, ...
Benchmarking data showed sourcing approach did not reliably predict timeline, quality, or execution performance across 133 ...
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across ...
Decentralized trial models have demonstrated real gains in enrollment performance and patient access, but operational switching costs, fragmented technology stacks, and unresolved gaps in the ...
In today's ACT Brief, we examine why seizure reduction misses what families want from epilepsy trials, how lab coordination ...
Why clinical development’s next AI bottleneck is not the model, but the system around it. “An AI-enabled workflow should identify the downstream implications of a change, propose aligned updates, ...
As the life sciences industry continues to evolve, the ability to effectively manage and leverage preclinical CRO ...
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results